Discussions with leaders: Herrmann and Czernin talk with Diane Simeone, MD, about her career achievements in advancing clinical research in pancreatic cancer.
Page 185
Trustworthy AI ecosystems: Saboury and members of an SNMMI task force outline opportunities and challenges in creating strategic plans for establishment of trustworthy artificial intelligence ecosystems in nuclear medicine.
Page 188
WB PET and whole-person research: Sundar and colleagues present a forward-looking assessment of the possibilities offered by total-body PET for investigating and illuminating multiorgan systemic interactions.
Page 197
Scientific integrity in nuclear medicine: Kwee and colleagues report on the results of an international survey of nuclear medicine scientists’ experience with scientific fraud, publication bias, and honorary authorship.
Page 200
SSTR procedure standard: Hope and colleagues detail consensus procedure guidelines intended to assist physicians in recommending, performing, interpreting, and reporting the results of somatostatin-receptor PET imaging in patients with neuroendocrine tumors.
Page 204
225Ac-DOTATATE TAT in GEP NETs: Ballal and colleagues evaluate long-term outcomes of targeted α-therapy with 225Ac-DOTATATE in patients with somatostatin receptor–expressing advanced-stage metastatic gastroenteropancreatic neuroendocrine tumors.
Page 211
Assessing 225Ac-TAT studies: Strosberg and colleagues offer perspective on results and analysis of a study in this issue of JNM reporting on real-world experience using targeted α-therapy in neuroendocrine tumor patients by radiolabeling DOTATATE with 225Ac.
Page 219
SPECT as 177Lu-PSMA-617 response biomarker: Pathmanandavel and colleagues investigate the predictive value of serial 177Lu-PSMA SPECT imaging in monitoring treatment response to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Page 221
Eligibility for 177Lu-PSMA-617 therapy in mCRPC: Cook and colleagues compare lesion and lesion–to–normal-organ ratios between 68Ga-PSMA-11 PET/CT and 99mTc-MIP-1404 SPECT/CT to evaluate eligibility for 177Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer.
Page 227
Cyclotron-produced 68Ga tracer: Tremblay and colleagues report on a comparison of DOTATATE labeling with 68Ga produced by a cyclotron or eluted from a generator to demonstrate safety and diagnostic efficacy of the cyclotron-produced radiopharmaceutical as a routine diagnostic tool.
Page 232
PRoLoG initiative on Lugano classification: Ricard and colleagues present the second in a 2-part series on consensus recommendations from academic and industry experts in lymphoma and imaging for consistent application of the Lugano lymphoma classification system.
Page 239
68Ga-FAPI PET/CT for IPMN: Lang and colleagues describe the clinical feasibility of accurate additional identification of intraductal papillary mucinous neoplasms by 68Ga-FAPI PET/CT in patients with MRI- or CT-proven cystic pancreatic lesions.
Page 244
Integrin αvβ3 PET in NENs: Carlsen and colleagues use 68Ga-NODAGA-E[c(RGDyK)]2 for PET/CT imaging of integrin αvβ3 in patients with neuroendocrine neoplasms and explore its potential utility in disease prognosis.
Page 252
SPECT MBF and MFR variability: Bailly and colleagues study intra- and interuser reproducibility of myocardial blood flow and myocardial flow reserve measurements in patients referred for dynamic cadmium zinc telluride–based pinhole cardiac SPECT.
Page 260
Early-phase amyloid PET and 18F-FDG PET: Boccalini and colleagues compare early-phase amyloid PET and 18F-FDG PET imaging at the individual level and report on their relative abilities to identify typical neurodegenerative patterns.
Page 266
LB copathology and PET in AD: Silva-Rodríguez and colleagues analyze relationships between neuropathologically assessed tau pathology, Lewy body pathology, substantia nigra neuronal loss, and antemortem 18F-FDG PET hypometabolism in patients with clinical Alzheimer disease presentation.
Page 274
Relative cerebral blood flow effects: Visser and colleagues compare semiquantitative and quantitative parameters of longitudinal 18F-flortaucipir PET scans in individuals with subjective cognitive decline or Alzheimer disease and explore the effects of changes in blood flow on these metrics.
Page 281
Skull binding in tau and amyloid PET: Flores and colleagues characterize the frequency of off-target [18F]flortaucipir skull binding on PET, its influence on estimates of Alzheimer disease pathology, and whether skull uptake is a stable feature across time and tracers.
Page 287
RSNA QIBA profile for amyloid PET: Smith and members of the Quantitative Imaging Biomarkers Alliance detail development and validation of a profile to characterize and reduce the variability of SUVRs in amyloid PET imaging, increasing statistical power and utility.
Page 294
Machine learning in PET/MRI: Morawitz and colleagues investigate whether machine learning prediction models based on simple assessable MRI or PET/MRI features can determine nodal status in newly diagnosed breast cancer for decision support in axillary lymph node staging.
Page 304
Fetal dose in PET/CT: Burton and colleagues provide radiation dose estimates to the fetus from PET/CT with protocols that are adapted to University of Michigan low-dose protocols for patients known to be pregnant.
Page 312
64Cu-LLP2A in MM: Laforest and colleagues report on preclinical and first-in-humans studies of safety and efficacy with this very late antigen 4–targeting radiopharmaceutical with promise for managing patients with multiple myeloma.
Page 320
90Y-FAPI PET quantification: Kersting and colleagues explore the conditions needed for reliable lesion image quantification in 90Y-FAPI radionuclide therapy using a digital PET/CT system.
Page 329
GD2 PET/MRI in sarcoma: Trautwein and colleagues present details on clinical [64Cu]Cu-DOTAGA-ch14.18/CHO PET/MRI to evaluate expression of the disialoganglioside GD2 in an osteosarcoma patient with pulmonary metastasis.
Page 337
- © 2023 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.